Literature DB >> 7888306

Molecular cloning and expression, in both COS-1 cells and S. cerevisiae, of a human cytosolic type-IVA, cyclic AMP specific phosphodiesterase (hPDE-IVA-h6.1).

M Sullivan1, M Egerton, Y Shakur, A Marquardsen, M D Houslay.   

Abstract

Screening a human T lymphocyte cDNA library with a phosphodiesterase (PDE) specific probe resulted in the isolation of two overlapping cDNA clones, h2.2 and h6.1, that encode a type IV, rolipram inhibited cAMP-specific PDE. Clones h2.2 and h6.1 were 1015 bp and 2288 bp in length, respectively, and overlapped for 984 bp with only one nucleotide difference. The h6.1 cDNA was extended at the 5'-end by 1304 bp, with respect to h2.2, and encoded an incomplete ORF (lacking an initiation codon) of 668 amino acids. The merged nucleotide sequence of h6.1/h2.2 exhibited 99.5% homology in the ORF (ten nucleotide changes resulting in six amino acid changes), and 95% homology in the 3'-untranslated region, with the previously reported human PDE-IVA cDNA [Livi G. P., Kmetz P., Mchale M. M., Cieslinski L. B., Sathe G. M., Taylor D. P., Davis R. L., Torphy T. J. and Balcarek J. M. (1990) Mol. Cell Biol. 10, 2678-2686]. The sequence reported for h6.1/h2.2 matched that found for IVA clones isolated from three other human cDNA libraries, a human genomic cosmid clone and pcr amplified products of the exon covering these differences in two individuals. The h6.1 cDNA was engineered to generate a complete ORF by building in the 56 bp, including the initiation codon, present in hPDE-IVA-Livi and missing from the 5'-end of h6.1, producing a cognate ORF encoding a protein of 687 amino acids but differing in five amino acids which lay in or adjacent to the putative catalytic domain. The complete h6.1 ORF was engineered for expression in both Saccharomyces cerevisiae and in COS-1 cells. Integration of a single copy of the engineered ORF of h6.1, under the transcriptional control of a constitutive yeast promoter, at the pep4 locus of a S. cerevisiae strain lacking both yeast PDE genes resulted in functional complementation of the yeast pde-phenotype. Yeast strains with functional PDE were a light creamy white colour, while strains devoid of PDE activity were a dull brown colour. Expression of h6.1 in COS-1 cells led to the production of a typical type IV PDE activity in that cAMP, but not cGMP, served as substrate and its activity was insensitive to either Ca2+/CaM or cGMP but was inhibited by low concentrations of rolipram.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888306     DOI: 10.1016/0898-6568(94)00039-5

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  12 in total

1.  Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase.

Authors:  S Spence; G Rena; M Sullivan; S Erdogan; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

Review 2.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family.

Authors:  I McPhee; L Pooley; M Lobban; G Bolger; M D Houslay
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

4.  Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected].

Authors:  Y M Horton; M Sullivan; M D Houslay
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

5.  Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase.

Authors:  G Scotland; M D Houslay
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

6.  Intracellular localization of the PDE4A cAMP-specific phosphodiesterase splice variant RD1 (RNPDE4A1A) in stably transfected human thyroid carcinoma FTC cell lines.

Authors:  L Pooley; Y Shakur; G Rena; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

7.  Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.

Authors:  S Erdogan; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

8.  Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells.

Authors:  R J Owens; C Catterall; D Batty; J Jappy; A Russell; B Smith; J O'Connell; M J Perry
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

9.  Induction of Ca2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms.

Authors:  S Spence; G Rena; G Sweeney; M D Houslay
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

10.  Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2.

Authors:  M Sullivan; G Rena; F Begg; L Gordon; A S Olsen; M D Houslay
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.